Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
Prolintane
Prolintane is a synthetic central nervous system stimulant1 of the phenylalkylpyrrolidine family with potential nootropic effects. First synthesized in the 1950s, it was marketed in Europe from the 1960s for its anti-fatigue and stimulant properties. It is structurally related to MDPV and A-PVP but produces milder effects, and it differs from A-PVP by lacking a ketone group. Case studies have reported adverse effects and recreational use of prolintane.1
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Pharmacology
Pharmacodynamics
Prolintane inhibits the reuptake of norepinephrine and dopamine, increasing their concentrations in the gap between neurons. This prolongs signaling through these neurotransmitters and contributes to its central nervous system stimulant action.
Pharmacokinetics
Tolerance
Harm Potential
Addiction & Dependence
Psychological
ModerateChronic use is described as mildly to moderately addictive, with moderate abuse potential, compulsive redosing risk, cravings, and psychological dependence in some users.
Toxicity
The exact toxic and lethal dosage is described as unknown, with no formal human studies available.
Higher doses can dangerously increase heart rate and blood pressure; stimulant combinations may add heart strain and, in extreme cases, heart failure.
Chronic abuse or single overdose exposure may produce psychotic symptoms, severe anxiety, mania, delusions, confusion, aggression, and irritability.
Psychosis Risk
Psychosis is described as possible after chronic abuse or a single overdose, and likely with extremely high doses or continued use.
Seizure Risk
Seizure risk is supported only by interaction warnings, especially with tramadol or highly stimulating combinations.
History & Culture
Prolintane was developed in the 1950s and was marketed in Europe from the 1960s as an antidepressant and analeptic. Historical applications included use as a mild central nervous system stimulant, a wakefulness agent, and an aid for cessation of cocaine use. It was also used in neuropsychiatric…
Legality
By Country
GermanyPrescription only
SwitzerlandNot scheduledReferences
Source Pages
Citations
Further Reading
Barceloux (2012) - Medical Toxicology of Drug Abuse
Drugs-Forum: Prolintane Discussion- Gillman (2005) - MAOIs and Serotonin Toxicity
- Kim et al. (2021) - Abuse Potential of Prolintane in Rodents
LOINC toxicology note – safety profile summary
MIMS monograph – adverse effects & interactions
Randomised trial – 10 mg & 20 mg prolintane vs placebo (1984)
Reddit: harm-reduction summary (clinical doses, 3-5 h half-life)
REM-sleep study – 15 mg & 30 mg doses- Talaie et al. (2009) - Tramadol Seizure Risk
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Prolintane article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
